We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Shares of Neurocrine Biosciences Inc. took a premarket nosedive Tuesday after
the Food and Drug Administration refused to approve the highest dose of the
biotech company's insomnia drug candidate.
